Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647661 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL1647658 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL18722237 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL19538490 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL14707760 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL3228008 | 1.00 | PYGB (0.58) | PYGBGAACA12CA1CA2 | |
| SCHEMBL9650344 | 0.98 | PYGB (0.55) | PYGBGAACA12CA1CA2 | |
| SCHEMBL8059606 | 0.98 | PYGB (0.55) | PYGBGAACA12CA1CA2 | |
| SCHEMBL23430833 | 0.82 | LGALS8 (0.53) | PYGBCA12CA1CA2CA9 | |
| SCHEMBL21894588 | 0.82 | LGALS8 (0.53) | PYGBCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018178-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT OR ANTI-VIRUS AGENT COMPRISING THE SAME | BIOMETRIX TECHNOLOGY INC (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20240018178-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT OR ANTI-VIRUS AGENT COMPRISING THE SAME | BIOMETRIX TECHNOLOGY INC (KR) | 2024-01-18 | — | — | US | disclosed |
| US-20230248702-A1 | MICELLE COMPRISING BENZIMIDAZOLE-CARBOHYDRATE CONJUGATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTICANCER AGENT OR ANTIVIRAL AGENT COMPRISING THE SAME | BIOMETRIX TECHNOLOGY INC. (KP) | 2023-08-10 | — | — | US | disclosed |
| US-20230248702-A1 | MICELLE COMPRISING BENZIMIDAZOLE-CARBOHYDRATE CONJUGATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTICANCER AGENT OR ANTIVIRAL AGENT COMPRISING THE SAME | BIOMETRIX TECHNOLOGY INC. (KP) | 2023-08-10 | — | — | US | disclosed |
| EP-3564239-B9 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20210395289-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT OR ANTI-VIRUS AGENT COMPRISING THE SAME | BIOMETRIX TECHNOLOGY INC (KR) | 2021-12-23 | — | — | US | disclosed |
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | IONIS PHARMACEUTICALS, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3677588-A1 | MODIFIED OLIGONUCLEOTIDES AND COMPOUND THAT CAN BE USED FOR SYNTHESIZING SAME | Guangzhou Ribobio Co., Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| US-9714421-B2 | Compositions and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2014179627-A2 | COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179625-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395289-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT OR ANTI-VIRUS AGENT COMPRISING THE SAME | ZC3HAV1, DDX41, ZC3HAV1L | PYGB 4870/4885GAA 1060/4885CA12 2668/4885 |
| US-20210277401-A1 | Compositions and Methods for Modulating PKK Expression | GCKR, PKM, PKLR | PYGB 148/4885GAA 746/4885CA12 4810/4885 |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | PYGB 4722/4885GAA 2744/4885CA12 3375/4885 |
| US-20230248702-A1 | MICELLE COMPRISING BENZIMIDAZOLE-CARBOHYDRATE CONJUGATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTICANCER AGENT OR ANTIVIRAL AGENT COMPRISING THE SAME | RB1, CCNI, CA14 | PYGB 2695/4885GAA 5/4885CA12 56/4885 |
| US-20240018178-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT OR ANTI-VIRUS AGENT COMPRISING THE SAME | ZC3HAV1, DDX41, ZC3HAV1L | PYGB 4870/4885GAA 1060/4885CA12 2668/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | PYGB 4722/4885GAA 2744/4885CA12 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.